IP Library › Patent Application 13112144
Patent Application
App. No. 13/112,144

SPERMICIDAL AND VIRUCIDAL PROPERTIES OF VARIOUS FORMS OF SOPHOROLIPIDS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/112,144
Abstract

Sophorolipid compounds having spermicidal and/or antiviral properties prepared by synthesizing the sophorolipid by fermentation of Candida bombicola in a fermentation media to form a natural mixture of lactonic sophorolipids compounds and non-lactonic sophorolipids compounds and utilizing the natural mixture as a spermicidal and/or antiviral agent, and/or separating the lactonic sophorolipids from the natural mixture to form a lactonic fraction and mixing all remaining fractions to form a non-lactonic fraction and utilizing the lactonic fraction and/or the non-lactonic fraction as an spermicidal and/or antiviral agent, and sophorolipid compounds for use as spermicidal and/or antiviral agents.

Claims (54)

1 . A contraceptive compound comprising a sophorolipid compound selected from the group consisting of:

a. 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate-6′,6″-diacetate;

b. Ethyl 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate;

c. Hexyl 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate; and

d. combinations thereof.

2 . The sophorolipid compound as claimed in claim 1 , further comprising a spermicidal agent.

3 . The sophorolipid compound as claimed in claim 1 , wherein the sophorolipid compound is 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate-6′,6″-diacetate.

4 . The sophorolipid compound as claimed in claim 3 , wherein the sophorolipid compound is in a form selected from the group consisting of a gel, a film, a foam, a suppository, a pessary, a liposomic formulation, as a liquid imbibed in a sponge, and as a liquid being released from an intravaginal or intrauterine delivery system.

5 . The sophorolipid compound as claimed in claim 3 , wherein the sophorolipid compound is synthesized by fermentation of Candida bombicola in a fermentation media to form a natural mixture of lactonic sophorolipids and non-lactonic sophorolipids in combination with at least one sophorolipid selected from the group consisting of:

a. 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate-6′,6″-diacetate;

b. Ethyl 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate;

c. Hexyl 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate; and

d. combinations thereof.

6 . The sophorolipid compound as claimed in claim 1 , wherein the sophorolipid compound is Ethyl 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate.

7 . The sophorolipid compound as claimed in claim 6 , wherein the sophorolipid compound is in a form selected from the group consisting of a gel, a film, a foam, a suppository, a pessary, a liposomic formulation, as a liquid imbibed in a sponge, and as a liquid being released from an intravaginal or intrauterine delivery system.

8 . The sophorolipid compound as claimed in claim 6 , wherein the sophorolipid compound is synthesized by fermentation of Candida bombicola in a fermentation media to form a natural mixture of lactonic sophorolipids and non-lactonic sophorolipids in combination with at least one sophorolipid selected from the group consisting of:

a. 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate-6′,6″-diacetate;

b. Ethyl 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate;

c. Hexyl 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate; and

d. combinations thereof.

9 . The sophorolipid compound as claimed in claim 1 , wherein the sophorolipid compound is Hexyl 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate.

10 . The sophorolipid compound as claimed in claim 9 , wherein the sophorolipid compound is in a form selected from the group consisting of a gel, a film, a foam, a suppository, a pessary, a liposomic formulation, as a liquid imbibed in a sponge, and as a liquid being released from an intravaginal or intrauterine delivery system.

11 . The sophorolipid compound as claimed in claim 9 , wherein the sophorolipid compound is synthesized by fermentation of Candida bombicola in a fermentation media to form a natural mixture of lactonic sophorolipids and non-lactonic sophorolipids in combination with at least one sophorolipid selected from the group consisting of:

a. 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate-6′,6″-diacetate;

b. Ethyl 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate;

c. Hexyl 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate; and

d. combinations thereof.

12 . An antiviral compound comprising a sophorolipid compound selected from the group consisting of:

a. 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate-6′,6″-diacetate;

b. Ethyl 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate;

c. Hexyl 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate; and

d. combinations thereof.

13 . The sophorolipid compound as claimed in claim 12 , further comprising an antiviral agent.

14 . The sophorolipid compound as claimed in claim 12 , wherein the sophorolipid compound is 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate-6′,6″-diacetate.

15 . The sophorolipid compound as claimed in claim 14 , wherein the sophorolipid compound is in a form selected from the group consisting of a gel, a film, a foam, a suppository, a pessary, a liposomic formulation, as a liquid imbibed in a sponge, and as a liquid being released from an intravaginal or intrauterine delivery system.

16 . The sophorolipid compound as claimed in claim 14 , wherein the sophorolipid compound is synthesized by fermentation of Candida bombicola in a fermentation media to form a natural mixture of lactonic sophorolipids and non-lactonic sophorolipids in combination with at least one sophorolipid selected from the group consisting of:

a. 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate-6′,6″-diacetate;

b. Ethyl 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate;

c. Hexyl 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate; and

d. combinations thereof.

17 . The sophorolipid compound as claimed in claim 12 , wherein the sophorolipid compound is Ethyl 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate.

18 . The sophorolipid compound as claimed in claim 17 , wherein the sophorolipid compound is in a form selected from the group consisting of a gel, a film, a foam, a suppository, a pessary, a liposomic formulation, as a liquid imbibed in a sponge, and as a liquid being released from an intravaginal or intrauterine delivery system.

19 . The sophorolipid compound as claimed in claim 17 , wherein the sophorolipid compound is synthesized by fermentation of Candida bombicola in a fermentation media to form a natural mixture of lactonic sophorolipids and non-lactonic sophorolipids in combination with at least one sophorolipid selected from the group consisting of:

a. 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate-6′,6″-diacetate;

b. Ethyl 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate;

c. Hexyl 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate; and

d. combinations thereof.

20 . The sophorolipid compound as claimed in claim 12 , wherein the sophorolipid compound is Hexyl 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate.

21 . The sophorolipid compound as claimed in claim 20 , wherein the sophorolipid compound is in a form selected from the group consisting of a gel, a film, a foam, a suppository, a pessary, a liposomic formulation, as a liquid imbibed in a sponge, and as a liquid being released from an intravaginal or intrauterine delivery system.

22 . The sophorolipid compound as claimed in claim 20 , wherein the sophorolipid compound is synthesized by fermentation of Candida bombicola in a fermentation media to form a natural mixture of lactonic sophorolipids and non-lactonic sophorolipids in combination with at least one sophorolipid selected from the group consisting of:

a. 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate-6′,6″-diacetate;

b. Ethyl 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate;

c. Hexyl 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate; and

d. combinations thereof.